- Home
- ITOC vs RDHL Comparison
ITOC vs RDHL Comparison
Compare ITOC & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITOC | RDHL |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | China | Israel |
| Employees | 7 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | ITOC | RDHL |
|---|---|---|
| Price | $0.33 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 148.8K |
| Earning Date | 03-20-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.71 |
| 52 Week High | $1.15 | $3.31 |
Technical Indicators
Market Signals| Indicator | ITOC | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 40.38 |
| Support Level | $0.29 | $0.76 |
| Resistance Level | $0.41 | $0.89 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 4.01 | 12.08 |
Price Performance
Historical ComparisonAbout ITOC iTonic Holdings Ltd Class A Ordinary Shares
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.